Key Highlights
- ADDF purchases 603,136 shares of Coya Therapeutics at $8.29 per share.
- Investment to fund Phase 2 trial of COYA 302 for Frontotemporal Dementia (FTD).
- COYA 302 aims to target neuroinflammation with a combination drug approach.
- Coya’s innovative therapies focus on enhancing regulatory T cell (Treg) function.
Source: Business Wire
Notable Quotes
- “Combination therapy will be integral to slowing – and eventually halting – cognitive decline for a disease as complex as FTD.” – Howard Fillit, M.D., Co-Founder and Chief Science Officer at ADDF
- “We are grateful that a world-renowned organization like the ADDF has chosen to support our corporate mission as well as the clinical development of COYA 302 through this equity investment.” – Howard Berman, Ph.D., Chief Executive Officer at Coya Therapeutics
SoHC's Take
The ADDF’s $5 million investment in Coya Therapeutics marks a significant endorsement of the potential of COYA 302 in treating Frontotemporal Dementia (FTD). This support underscores the growing recognition of combination therapies targeting neuroinflammation as a promising approach for complex neurodegenerative diseases. Coya’s focus on regulatory T cells (Tregs) to restore immune balance highlights a novel pathway that could offer durable and sustained benefits, addressing a critical unmet need in the treatment landscape for Alzheimer’s and related dementias.
